Despite being the strongest blood vessel constrictor known, urotensin-II levels and gene expression were unchanged in heart failure patients, suggesting it doesn't play a major role in the disease.
No change in U-II levelsUrotensin-II — the strongest vasoconstrictor known — showed no elevation in heart failure patients even after hemodynamic improvement from therapy
What the researchers found
Urotensin-II plasma levels and its gene expression in heart and blood vessels were unchanged in patients with congestive heart failure compared to healthy controls. The peptide levels did not differ across measurement sites (pulmonary artery, left ventricle, coronary sinus, or arm vein), and even when severe heart failure patients received vasodilator therapy that significantly improved their hemodynamics (cardiac index up 78%, wedge pressure down 55%), urotensin-II levels stayed flat over 24 hours.
Gene expression of the urotensin-II precursor in heart tissue and blood vessels was also no different between end-stage heart failure patients and controls with normal heart function.
Why it matters
Urotensin-II had been identified as the most potent vasoconstrictor known, which made it a prime suspect in heart failure — a condition where blood vessels constrict too much and the heart can't keep up. This study provided early evidence that despite its powerful vasoconstrictor ability, urotensin-II doesn't appear to play a major role in human heart failure, redirecting research efforts toward other peptide targets.
The numbers in context
n=34 · Controls CI 3.5 l/min/m² · Severe CHF CI 1.8 l/min/m² · Vasodilator therapy: CI +78%, PCWP -55% · No change in U-II over 24h
How the study worked
Researchers compared three groups: 13 healthy controls, 10 patients with moderate heart failure, and 11 with severe heart failure. They measured urotensin-II levels in blood drawn from four different locations in the cardiovascular system. They also checked gene expression of the urotensin-II precursor in heart tissue and blood vessels using RT-PCR. In severe heart failure patients who received vasodilator therapy, they tracked urotensin-II levels over 24 hours.
Who was studied
Adults with moderate or severe congestive heart failure and healthy controls
What this study cannot tell us
Small sample size (34 total participants). Single-center study. Only measured circulating levels and gene expression — did not assess receptor expression or local tissue activity. The 24-hour monitoring window may have been too short to capture slower changes.
How to read the evidence
This is an observational clinical study with a small but well-characterized patient population. It includes both circulating biomarker measurements and gene expression data, with hemodynamic monitoring, but the sample size limits statistical power.
When this study was published
Published in 2002, this was an early investigation into urotensin-II's role in heart failure. Subsequent research has largely confirmed that urotensin-II is not a primary driver of CHF, though its role in other cardiovascular conditions continues to be studied.
The bigger picture
This study is part of the broader effort to identify which vasoactive peptides actually contribute to heart failure. While urotensin-II's extreme potency as a vasoconstrictor made it a logical suspect, this negative finding helped narrow the field and redirect attention to other peptide systems like natriuretic peptides and endothelin that have proven more relevant to heart failure pathophysiology.
Questions still open
- Could urotensin-II receptor expression or sensitivity change in heart failure even if the peptide levels don't?
- Does urotensin-II play a role in other cardiovascular conditions like pulmonary hypertension rather than systemic heart failure?
- Would longer monitoring periods or larger patient populations reveal subtle changes in urotensin-II dynamics?
Common questions
What is urotensin-II and why was it suspected in heart failure?
Did treatment for heart failure affect urotensin-II levels?
Read the original research
Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.
Regulatory peptides, 110(1), 33-8
Citation
Dschietzig, Thomas; Bartsch, Cornelia; Pregla, Rainer; Zurbrügg, Heinz Robert; Armbruster, Franz Paul; Richter, Christoph; Laule, Michael; Romeyke, Elfrun; Neubert, Charlotte; Voelter, Wolfgang; Baumann, Gert; Stangl, Karl. (2002). Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.. Regulatory peptides, 110(1), 33-8.